REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION

REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION was reported 55 times

REACTIVE CAPILLARY ENDOTHELIAL PROLIFERATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PENPULIMAB 1 0.0102
1 PLATINUM 1 0.0019
2 FRUQUINTINIB 2 0.0005
3 ATEZOLIZUMAB 15 0.0004
4 REGORAFENIB 4 0.0003
5 CISPLATIN 21 0.0003
6 DOCETAXEL 18 0.0003
7 DOCETAXEL ANHYDROUS 18 0.0003
8 SORAFENIB 5 0.0002
9 LENVATINIB 7 0.0002
10 CAPECITABINE 19 0.0002
11 LEUCOVORIN CALCIUM 4 0.0002
12 DURVALUMAB 4 0.0002
13 VEMURAFENIB 2 0.0002
14 RAMUCIRUMAB 1 0.0002
15 OXALIPLATIN 12 0.0002
16 LORLATINIB 1 0.0001
17 PEMETREXED DISODIUM 5 0.0001
18 BEVACIZUMAB 16 0.0001
19 PEMBROLIZUMAB 12 0.0001
20 IRINOTECAN HYDROCHLORIDE 1 0.0001
21 LAPATINIB 1 0.0001
22 CETUXIMAB 2 0.0001
23 GEMCITABINE HYDROCHLORIDE 3 0.0001
24 FLUOROURACIL CREAM, 0.5% 4 0.0001
25 NIVOLUMAB 5 0.0001
26 FLUOROURACIL 4 0.0001
27 DABRAFENIB 1 0.0000
28 CARBOPLATIN 6 0.0000
29 TRASTUZUMAB 3 0.0000
30 TRAMETINIB 1 0.0000
31 PACLITAXEL 4 0.0000
32 PAZOPANIB HYDROCHLORIDE 1 0.0000
33 PERTUZUMAB 1 0.0000
34 ETOPOSIDE 2 0.0000
35 CABOZANTINIB 1 0.0000
36 MYCOPHENOLATE MOFETIL 1 0.0000
37 MYCOPHENOLATE MOFETIL HYDROCHLORIDE 1 0.0000